Circulating short-chain fatty acids in type 2 diabetic patients and overweight/obese individuals

Salamone, Dominic; Costabile, Giuseppina; Corrado, Alessandra; Pepa, Giuseppe Della; Vitale, Marilena; Giacco, Rosalba; Luongo, Diomira; Testa, Roberta; Rivellese, Angela Albarosa; Annuzzi, Giovanni; Bozzetto, Lutgarda

doi:10.1007/s00592-022-01934-8

Cited by 4 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The circulating levels of SCFAs were significantly lower in patients with T2D, where propionic acid levels showed a trend of negative correlation with IR [69]. In addition, a clinical study discovered a link between stool SCFA levels, body mass index, and IR [70].…”

Section: Short-chain Fatty Acidsmentioning

confidence: 97%

A Metabolite Perspective on the Involvement of the Gut Microbiota in Type 2 Diabetes

Fu,

Li,

Xiao

et al. 2023

IJMS

View full text Add to dashboard Cite

Type 2 diabetes (T2D) is a commonly diagnosed condition that has been extensively studied. The composition and activity of gut microbes, as well as the metabolites they produce (such as short-chain fatty acids, lipopolysaccharides, trimethylamine N-oxide, and bile acids) can significantly impact diabetes development. Treatment options, including medication, can enhance the gut microbiome and its metabolites, and even reverse intestinal epithelial dysfunction. Both animal and human studies have demonstrated the role of microbiota metabolites in influencing diabetes, as well as their complex chemical interactions with signaling molecules. This article focuses on the importance of microbiota metabolites in type 2 diabetes and provides an overview of various pharmacological and dietary components that can serve as therapeutic tools for reducing the risk of developing diabetes. A deeper understanding of the link between gut microbial metabolites and T2D will enhance our knowledge of the disease and may offer new treatment approaches. Although many animal studies have investigated the palliative and attenuating effects of gut microbial metabolites on T2D, few have established a complete cure. Therefore, conducting more systematic studies in the future is necessary.

show abstract

Section: Short-chain Fatty Acidsmentioning

confidence: 97%

A Metabolite Perspective on the Involvement of the Gut Microbiota in Type 2 Diabetes

Fu,

Li,

Xiao

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Its decreased concentration has been associated with increased permeability of the intestinal tract ( Letchumanan et al., 2022 ). Furthermore, T2D patients exhibit lower levels of SCFAs such as acetic acid, propionic acid, and butyric acid ( Salamone et al., 2022 ). The dysbiosis of the gut microbiota community, along with the shortage of SCFAs, compromise the integrity and function of the gut barrier, thereby exacerbating T2D symptoms.…”

Section: Tcm Alleviate Diseases Via Regulating Gut Microbiota and Gut...mentioning

confidence: 99%

Repairing gut barrier by traditional Chinese medicine: roles of gut microbiota

Zhou,

Zhang,

Cheng

et al. 2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Gut barrier is not only part of the digestive organ but also an important immunological organ for the hosts. The disruption of gut barrier can lead to various diseases such as obesity and colitis. In recent years, traditional Chinese medicine (TCM) has gained much attention for its rich clinical experiences enriched in thousands of years. After orally taken, TCM can interplay with gut microbiota. On one hand, TCM can modulate the composition and function of gut microbiota. On the other hand, gut microbiota can transform TCM compounds. The gut microbiota metabolites produced during the actions of these interplays exert noticeable pharmacological effects on the host especially gut barrier. Recently, a large number of studies have investigated the repairing and fortifying effects of TCM on gut barriers from the perspective of gut microbiota and its metabolites. However, no review has summarized the mechanism behand this beneficiary effects of TCM. In this review, we first briefly introduce the unique structure and specific function of gut barrier. Then, we summarize the interactions and relationship amidst gut microbiota, gut microbiota metabolites and TCM. Further, we summarize the regulative effects and mechanisms of TCM on gut barrier including physical barrier, chemical barrier, immunological barrier, and microbial barrier. At last, we discuss the effects of TCM on diseases that are associated gut barrier destruction such as ulcerative colitis and type 2 diabetes. Our review can provide insights into TCM, gut barrier and gut microbiota.

show abstract

“…Встановлено тенденцію до зниження сироваткового вмісту КЛВЖК у 1,7 раза (р > 0,05) у ІІ групі пацієнтів порівняно з І групою. Отримані нами дані узгоджуються з результатами досліджень в осіб із надмірною вагою/ожирінням [18].…”

Section: обговоренняunclassified

Metabolism of free fatty acids in patients with gastrointestinal diseases depending on the body mass index

Stepanov¹,

Mosiychuk²,

Кленіна³

et al. 2023

GASTRO

View full text Add to dashboard Cite

Background. The purpose of the study is to analyze the content of free fatty acids (FFA) in the blood serum of overweight and underweight patients with gastrointestinal diseases. Materials and methods. Thirty-one patients with gastrointestinal diseases were examined, 19 (61.3 %) men and 12 (38.7 %) women with a median age of 39 (27; 48) years. Depending on the results of the body composition study with the multifunctional monitor TANITA MC-780MA (Japan), they were divided into the following groups: overweight patients (body mass index (BMI) more than 25.0 kg/m2) and underweight persons (BMI below 18.5 kg/m2). Determination of the FFA spectrum in the blood serum was carried out using a gas chromatograph with a flame ionization detector Chromatek-Crystal 5000. The control group consisted of 16 practically healthy people. Statistical processing of the results was carried out using the Statistica 6.1 application program package. Results. Patients with a change in body weight reported a statistically significant decrease in the median total content of short-chain saturated FFA (C4:0) mainly due to a decrease in the butyric acid content by 67 times (p = 0.001) with increased BMI and by 114 times (p = 0.002) with decreased BMI compared to controls. At the same time, the analysis of the serum spectrum of saturated FFA with an average carbon chain length showed a probable increase in the content of capric acid by 14 times (p < 0.01), undecyl acid by 19 times (p < 0.01), and lauric acid by 25 times (p < 0.001) in patients with changes in body weight. The content of caproic acid increased in the group with excessive body weight by 3.9 times (p = 0.046) compared to controls and by 2.6 times (p > 0.05) compared to underweight patients. The total content of monounsaturated FFA in the blood serum of patients with increased and decreased BMI increased significantly by 32 times (p < 0.001) and 19 times (p = 0.001), respectively, compared to controls. The total content of polyunsaturated FFA in the blood serum of patients of both groups was found in a trace amount. Overweight patients had a 38-fold (p < 0.01) increase in the trans-FFA elaidic acid (C18:1(trans-9)) compared to controls, while underweight patients had a decrease in linoelaidic acid (C18:2(trans-9,12)) by 11.7 times (p < 0.05). Correlation analysis revealed a positive relationship between BMI and increased serum content of saturated caproic acid (r = 0.39; p = 0.019); monounsaturated acids — palmitoleic (r = 0.33; р = 0.045) and heptadecenoic (r = 0.35; р = 0.034); trans-configuration fatty acids — elaidic (r = 0.43; p = 0.009) and linoelaidic (r = 0.43; p = 0.007). Conclusions. Patients with gastrointestinal diseases had an imbalance in the fatty acid spectrum of the blood serum. Against the background of the tendency to decrease the total content of short-chain saturated FFA, a significant increase in the content of monounsaturated FFA and trans-FFA was noted, especially with increased BMI. In all patients, the trace amount of polyunsaturated FFA fractions was found. The obtained results can be used to improve the differential treatment of metabolic disorders in patients with gastrointestinal tract pathology.

show abstract

Circulating short-chain fatty acids in type 2 diabetic patients and overweight/obese individuals

Cited by 4 publications

References 5 publications

A Metabolite Perspective on the Involvement of the Gut Microbiota in Type 2 Diabetes

A Metabolite Perspective on the Involvement of the Gut Microbiota in Type 2 Diabetes

Repairing gut barrier by traditional Chinese medicine: roles of gut microbiota

Metabolism of free fatty acids in patients with gastrointestinal diseases depending on the body mass index

Contact Info

Product

Resources

About